Vigabatrin Only Product for Coma

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Coma+2 More
Vigabatrin Only Product - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new treatment for seizures that occur after a person has been without oxygen for a period of time.

Eligible Conditions
  • Coma
  • Status Epilepticus, Electrographic

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: up to day 7

up to day 7
Vigabatrin levels

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

Trial Design

1 Treatment Group

Open label
1 of 1

Experimental Treatment

22 Total Participants · 1 Treatment Group

Primary Treatment: Vigabatrin Only Product · No Placebo Group · Phase 2

Open label
Drug
Experimental Group · 1 Intervention: Vigabatrin Only Product · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to day 7

Who is running the clinical trial?

American Heart AssociationOTHER
281 Previous Clinical Trials
5,823,712 Total Patients Enrolled
1 Trials studying Coma
14 Patients Enrolled for Coma
Yale UniversityOTHER
1,667 Previous Clinical Trials
21,074,655 Total Patients Enrolled
Thomas Jefferson UniversityOTHER
400 Previous Clinical Trials
131,177 Total Patients Enrolled
University of FloridaLead Sponsor
1,237 Previous Clinical Trials
698,431 Total Patients Enrolled
Carolina B Maciel, MD, MSCRPrincipal InvestigatorUniversity of Florida

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 26th, 2021

Last Reviewed: November 3rd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.